Long--term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data
2023
Abstract
Siponimod significantly reduced the risk of confirmed disability progression, worsening in cognitive processing speed, relapses, and magnetic resonance imaging measures of brain atrophy and inflammation in secondary progressive multiple sclerosis patients. Data from the 5-year extension of the EXPAND study support the importance of early detection of secondary progressive multiple sclerosis and thus early initiation of siponimod treatment.